{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:23:16Z","timestamp":1792419796895,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.prp.2026.156506","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:40:29Z","timestamp":1777527629000},"page":"156506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2\u2013TP53, EGFR, and PI3K\/AKT\/mTOR"],"prefix":"10.1016","volume":"283","author":[{"given":"Nitin Kumar","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firoz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7374-0283","authenticated-orcid":false,"given":"Adil","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"Ca"},{"issue":"10","key":"10.1016\/j.prp.2026.156506_bib2","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3390\/cancers17101599","article-title":"The Role of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma: Recent Advancements and Emerging Therapeutic Strategies","volume":"17","author":"Glapi\u0144ski","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/cancers13040799","article-title":"Targeted therapies for pancreatic cancer: overview of current treatments and new opportunities for personalized oncology","volume":"13","author":"Leroux","year":"2021","journal-title":"Cancers"},{"issue":"29","key":"10.1016\/j.prp.2026.156506_bib4","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","article-title":"CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicentre randomized phase III trial","volume":"35","author":"Sinn","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.prp.2026.156506_bib5","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156506_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1038650","article-title":"Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression","volume":"13","author":"Dong","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-pharmtox-022823-113946","article-title":"Direct K-Ras inhibitors to treat cancers: progress, new insights, and approaches to treat resistance","volume":"64","author":"Nussinov","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.prp.2026.156506_bib8","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/diagnostics12051058","article-title":"Molecular characterization of pancreatic ductal adenocarcinoma using a next-generation sequencing custom-designed multigene panel","volume":"12","author":"Malvi","year":"2022","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/biom13010067","article-title":"Cancer-associated fibroblast heterogeneity, activation and function: implications for prostate cancer","volume":"13","author":"Owen","year":"2022","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.prp.2026.156506_bib10","first-page":"762","article-title":"Drugging the \u2018undruggable\u2019KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer","volume":"22","author":"Khan","year":"2025","journal-title":"Cancer Biol. & Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13000-025-01637-y","article-title":"A novel KRAS exon 2 drop-off digital PCR assay for mutation detection in cell-free DNA of cancer patients","volume":"20","author":"Addamo-De Nard","year":"2025","journal-title":"Diagn. Pathol."},{"issue":"19","key":"10.1016\/j.prp.2026.156506_bib12","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1158\/0008-5472.CAN-17-3939","article-title":"Discovery and characterization of dual inhibitors of MDM2 and NFAT1 for pancreatic cancer therapy","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib13","doi-asserted-by":"crossref","first-page":"C233","DOI":"10.1152\/ajpcell.00079.2020","article-title":"Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer","volume":"319","author":"Huang","year":"2020","journal-title":"Am. J. Physiol. -Cell Physiol."},{"issue":"19","key":"10.1016\/j.prp.2026.156506_bib14","doi-asserted-by":"crossref","first-page":"10219","DOI":"10.3390\/ijms221910219","article-title":"Highlights on the role of KRAS mutations in reshaping the microenvironment of pancreatic adenocarcinoma","volume":"22","author":"Hafezi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40169-019-0226-9","article-title":"Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma","volume":"8","author":"Daniel","year":"2019","journal-title":"Clin. Transl. Med."},{"issue":"9","key":"10.1016\/j.prp.2026.156506_bib16","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.3390\/ijms21093218","article-title":"Pancreatic cancer and its microenvironment\u2014recent advances and current controversies","volume":"21","author":"Stopa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156506_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1625114","article-title":"The role of inflammatory factors in the tumor microenvironment of pancreatic cancer","volume":"16","author":"Yuan","year":"2025","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.prp.2026.156506_bib18","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.3390\/cancers13215481","article-title":"Oncogenic KRAS-induced feedback inflammatory signaling in pancreatic cancer: an overview and new therapeutic opportunities","volume":"13","author":"Bansod","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1146\/annurev.bi.56.070187.004023","article-title":"Ras genes","volume":"56","author":"Barbacid","year":"1987","journal-title":"Annu. Rev. Biochem."},{"issue":"23","key":"10.1016\/j.prp.2026.156506_bib20","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1093\/nar\/11.23.8221","article-title":"Regional chromosomal localization of N-ras, K-ras-1, K-ras-2, and myb oncogenes in human cells","volume":"11","author":"McBride","year":"1983","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.prp.2026.156506_bib21","first-page":"246","article-title":"Properties of a murine sarcoma virus","volume":"36","author":"Kirsten","year":"1970","journal-title":"Bibl. Haematol."},{"issue":"16","key":"10.1016\/j.prp.2026.156506_bib22","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1073\/pnas.79.16.4848","article-title":"Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses","volume":"79","author":"Chang","year":"1982","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.prp.2026.156506_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm2438","article-title":"Ras oncogenes: split personalities","volume":"9","author":"Karnoub","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib24","first-page":"259","article-title":"K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer","volume":"25","author":"Plowman","year":"2006","journal-title":"Journal experimental & clinical cancer research CR"},{"issue":"10","key":"10.1016\/j.prp.2026.156506_bib25","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1096\/fasebj.3.10.2666231","article-title":"Structural and functional properties of ras proteins","volume":"3","author":"Santos","year":"1989","journal-title":"FASEB J."},{"issue":"5545","key":"10.1016\/j.prp.2026.156506_bib26","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1126\/science.1062023","article-title":"The guanine nucleotide-binding switch in three dimensions","volume":"294","author":"Vetter","year":"2001","journal-title":"Science"},{"issue":"6305","key":"10.1016\/j.prp.2026.156506_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/349117a0","article-title":"The GTPase superfamily: conserved structure and molecular mechanism","volume":"349","author":"Bourne","year":"1991","journal-title":"nature"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1152\/physrev.2001.81.1.153","article-title":"Small GTP-binding proteins","volume":"81","author":"Takai","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.prp.2026.156506_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0789-x","article-title":"KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target","volume":"17","author":"Rom\u00e1n","year":"2018","journal-title":"Mol. Cancer"},{"issue":"45","key":"10.1016\/j.prp.2026.156506_bib30","doi-asserted-by":"crossref","first-page":"35021","DOI":"10.1074\/jbc.M004386200","article-title":"The Ras\/p120 GTPase-activating protein (GAP) interaction is regulated by the p120 GAP plastron homology domain","volume":"275","author":"Drugan","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.prp.2026.156506_bib31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: critical elements in the control of small G proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"issue":"6192","key":"10.1016\/j.prp.2026.156506_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.1250373","article-title":"Ras activation by SOS: Allosteric regulation by altered fluctuation dynamics","volume":"345","author":"Iversen","year":"2014","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.biochi.2008.10.010","article-title":"p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling","volume":"91","author":"Pamonsinlapatham","year":"2009","journal-title":"Biochimie"},{"key":"10.1016\/j.prp.2026.156506_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jbior.2015.06.003","article-title":"Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells","volume":"59","author":"Fitzgerald","year":"2015","journal-title":"Adv. Biol. Regul."},{"issue":"6","key":"10.1016\/j.prp.2026.156506_bib35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/21541248.2016.1251383","article-title":"Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer","volume":"9","author":"Chu","year":"2018","journal-title":"Small GTPases"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib36","first-page":"83","article-title":"Erlotinib in the treatment of advanced pancreatic cancer","volume":"2","author":"Kelley","year":"2008","journal-title":"Biol. Targets Ther."},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.25259\/IJMIO_29_2022","article-title":"Signaling pathways in pancreatic ductile adenocarcinoma and potential therapeutic targets","volume":"8","author":"McHugh","year":"2023","journal-title":"Int. J. Mol. Immuno Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib38","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-022-01384-3","article-title":"Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma","volume":"15","author":"Tong","year":"2022","journal-title":"J. Hematol. & Oncol."},{"issue":"7592","key":"10.1016\/j.prp.2026.156506_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.prp.2026.156506_bib42","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","article-title":"Proteogenomic characterization of pancreatic ductal adenocarcinoma","volume":"184","author":"Cao","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.53588","article-title":"KRAS mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma","volume":"8","author":"Norton","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.prp.2026.156506_bib44","doi-asserted-by":"crossref","DOI":"10.1039\/D5MD00740B","article-title":"An overview of recent advancements in targeted cancer therapies and their potential clinical impact","author":"Ahmed","year":"2026","journal-title":"RSC Med. Chem."},{"issue":"14","key":"10.1016\/j.prp.2026.156506_bib45","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/cells13141221","article-title":"KRAS mutation subtypes and their association with other driver mutations in oncogenic pathways","volume":"13","author":"Mondal","year":"2024","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib46","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/jgh3.12530","article-title":"Digital next-generation sequencing of cell-free DNA for pancreatic cancer","volume":"5","author":"Takano","year":"2021","journal-title":"JGH Open"},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib47","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/cas.16104","article-title":"Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer","volume":"115","author":"Lee","year":"2024","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.prp.2026.156506_bib48","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/cancers13050994","article-title":"Circulating tumor DNA detection by digital-droplet PCR in pancreatic ductal adenocarcinoma: a systematic review","volume":"13","author":"Huerta","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/cancers18010089","article-title":"FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies","volume":"18","author":"He","year":"2025","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.prp.2026.156506_bib50","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.3390\/cancers14143451","article-title":"TP53-status-dependent oncogenic EZH2 activity in pancreatic cancer","volume":"14","author":"Versemann","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/1078-0432.CCR-25-1982","article-title":"Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach","volume":"32","author":"Adesoye","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156506_bib52","series-title":"Personalized Medicine in Oncology: Precision Oncology and Transformative Technologies","first-page":"99","article-title":"Targeted Therapies for Solid Tumors","author":"Hays","year":"2026"},{"issue":"17","key":"10.1016\/j.prp.2026.156506_bib53","doi-asserted-by":"crossref","first-page":"10132","DOI":"10.3390\/ijms231710132","article-title":"Targeting PI3K\/AKT\/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects","volume":"23","author":"Stanciu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.prp.2026.156506_bib54","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/genes11091098","article-title":"Building towards precision oncology for pancreatic cancer: real-world challenges and opportunities","volume":"11","author":"Wang","year":"2020","journal-title":"Genes"},{"issue":"19","key":"10.1016\/j.prp.2026.156506_bib55","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.3390\/cancers13194932","article-title":"The heterogeneity of the tumor microenvironment as essential determinant of development, progression and therapy response of pancreatic cancer","volume":"13","author":"Group Young Researchers in Inflammatory Carcinogenesis","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/life13010031","article-title":"Assessment of thermal stability of mutant p53 proteins via differential scanning fluorimetry","volume":"13","author":"Khadiullina","year":"2022","journal-title":"Life"},{"issue":"7","key":"10.1016\/j.prp.2026.156506_bib57","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/ijc.29663","article-title":"Transcription factors that interact with p53 and M dm2","volume":"138","author":"Inoue","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"23","key":"10.1016\/j.prp.2026.156506_bib58","doi-asserted-by":"crossref","first-page":"16531","DOI":"10.1074\/jbc.274.23.16531","article-title":"Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2","volume":"274","author":"Maki","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib59","article-title":"Characterization of cancer-associated missense mutations in MDM2","volume":"3","author":"Chauhan","year":"2016","journal-title":"Mol. & Cell. Oncol."},{"key":"10.1016\/j.prp.2026.156506_bib60","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00280-010-1486-7","article-title":"The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention","volume":"68","author":"Peirce","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.prp.2026.156506_bib61","first-page":"882","article-title":"Recent advances in validating MDM2 as a cancer target","volume":"9","author":"Rayburn","year":"2009","journal-title":"Anti-Cancer Agents Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1568009053332636","article-title":"MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy","volume":"5","author":"Rayburn","year":"2005","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib63","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1146\/annurev-pathol-012414-040349","article-title":"The roles of MDM2 and MDMX in cancer","volume":"11","author":"Karni-Schmidt","year":"2016","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156506_bib65","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-94-017-9211-0_13","article-title":"p53-independent effects of Mdm2","author":"Bohlman","year":"2014","journal-title":"Mutant p53 MDM2 Cancer"},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib66","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7555\/JBR.27.20130030","article-title":"The MDM2-p53 pathway revisited","volume":"27","author":"Nag","year":"2013","journal-title":"J. Biomed. Res."},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib67","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2016.08.015","article-title":"Discovery of dual inhibitors of MDM2 and XIAP for cancer treatment","volume":"30","author":"Gu","year":"2016","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib68","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1021\/jm501092z","article-title":"Small-molecule inhibitors of the MDM2\u2013p53 protein\u2013protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment: miniperspective","volume":"58","author":"Zhao","year":"2015","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.prp.2026.156506_bib69","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.prp.2026.156506_bib70","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/cells14080583","article-title":"Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2\/MdmX Interaction","volume":"14","author":"Huang","year":"2025","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.prp.2026.156506_bib71","doi-asserted-by":"crossref","first-page":"11623","DOI":"10.1073\/pnas.90.24.11623","article-title":"The mdm-2 gene is induced in response to UV light in a p53-dependent manner","volume":"90","author":"Perry","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"52","key":"10.1016\/j.prp.2026.156506_bib72","doi-asserted-by":"crossref","first-page":"50607","DOI":"10.1074\/jbc.C200578200","article-title":"Acetylation of p53 inhibits its ubiquitination by Mdm2","volume":"277","author":"Li","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.prp.2026.156506_bib73","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1073\/pnas.0308762101","article-title":"Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo","volume":"101","author":"Luo","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.prp.2026.156506_bib74","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/carcin\/bgs145","article-title":"p53 N-terminal phosphorylation: a defining layer of complex regulation","volume":"33","author":"Jenkins","year":"2012","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.prp.2026.156506_bib75","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jmb.2004.06.071","article-title":"Cooperative binding of tetrameric p53 to DNA","volume":"341","author":"Weinberg","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"6","key":"10.1016\/j.prp.2026.156506_bib76","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.molcel.2006.05.015","article-title":"Structural basis of DNA recognition by p53 tetramers","volume":"22","author":"Kitayner","year":"2006","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib77","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"19","key":"10.1016\/j.prp.2026.156506_bib78","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1158\/1078-0432.CCR-21-0715","article-title":"Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53","volume":"27","author":"Saleh","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2026.156506_bib79","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s10637-021-01141-2","article-title":"Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors","volume":"39","author":"Italiano","year":"2021","journal-title":"Investig. N. Drugs"},{"issue":"14","key":"10.1016\/j.prp.2026.156506_bib80","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3390\/cells11142155","article-title":"Effects of TP53 mutations and miRs on immune responses in the tumor microenvironment important in pancreatic cancer progression","volume":"11","author":"McCubrey","year":"2022","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.prp.2026.156506_bib81","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/biom15081088","article-title":"The Multifaceted Role of p53 in Cancer Molecular Biology: Insights for Precision Diagnosis and Therapeutic Breakthroughs","volume":"15","author":"Xu","year":"2025","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.prp.2026.156506_bib82","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.immuni.2025.06.005","article-title":"Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer","volume":"58","author":"Mahat","year":"2025","journal-title":"Immunity"},{"issue":"19","key":"10.1016\/j.prp.2026.156506_bib83","doi-asserted-by":"crossref","first-page":"10219","DOI":"10.3390\/ijms221910219","article-title":"Highlights on the role of KRAS mutations in reshaping the microenvironment of pancreatic adenocarcinoma","volume":"22","author":"Hafezi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib84","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13046-019-1094-2","article-title":"Clinical development of targeted and immune based anti-cancer therapies","volume":"38","author":"Seebacher","year":"2019","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156506_bib85","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40265-019-01113-0","article-title":"Targeting EGFR and RAS\/RAF signaling in the treatment of metastatic colorectal cancer: from current treatment strategies to future perspectives","volume":"79","author":"Mizukami","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib86","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/cells8040316","article-title":"Structure and dynamics of the EGF receptor as revealed by experiments and simulations and its relevance to non-small cell lung cancer","volume":"8","author":"Martin-Fernandez","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.prp.2026.156506_bib87","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fonc.2019.00099","article-title":"Targeting molecular pathways in intracranial metastatic disease","volume":"9","author":"Venur","year":"2019","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib88","first-page":"520","article-title":"Recent advances on the roles of epidermal growth factor receptor in psoriasis","volume":"11","author":"Wang","year":"2019","journal-title":"Am. J. Transl. Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib89","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ajcp\/aqz010","article-title":"Pathologic features and clinical implications of breast cancer with HER2 intratumoral genetic heterogeneity: an institutional review","volume":"152","author":"Muller","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"issue":"56","key":"10.1016\/j.prp.2026.156506_bib90","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","article-title":"The EGF receptor family as targets for cancer therapy","volume":"19","author":"Mendelsohn","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2026.156506_bib91","doi-asserted-by":"crossref","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","author":"Olayioye","year":"2000","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib92","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.radonc.2004.07.012","article-title":"Effect of reduced EGFR function on the radiosensitivity and proliferative capacity of mouse jejunal crypt clonogens","volume":"72","author":"Iyer","year":"2004","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib93","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers3021513","article-title":"Epidermal growth factor receptor in pancreatic cancer","volume":"3","author":"Oliveira-Cunha","year":"2011","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.prp.2026.156506_bib94","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib95","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.phrs.2010.03.005","article-title":"Targeting nanoparticles to cancer","volume":"62","author":"Wang","year":"2010","journal-title":"Pharmacol. Res."},{"issue":"14","key":"10.1016\/j.prp.2026.156506_bib96","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2174\/1389450115666141125123003","article-title":"EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies","volume":"15","author":"Nedaeinia","year":"2014","journal-title":"Curr. Drug Targets"},{"issue":"9","key":"10.1016\/j.prp.2026.156506_bib97","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib98","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/biom9020067","article-title":"Getting the Akt together: guiding intracellular Akt activity by PI3K","volume":"9","author":"Yudushkin","year":"2019","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.prp.2026.156506_bib99","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1080\/15548627.2015.1043076","article-title":"Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy","volume":"11","author":"Yu","year":"2015","journal-title":"Autophagy"},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/cancers9030024","article-title":"Class (I) phosphoinositide 3-kinases in the tumor microenvironment","volume":"9","author":"Gyori","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156506_bib101","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-94-007-3012-0_6","article-title":"Phosphoinositide 3-kinases in health and disease","author":"Ghigo","year":"2012","journal-title":"Phosphoinositides I Enzymes Synthesis Degradation"},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib102","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1042\/BST0370615","article-title":"Form and flexibility in phosphoinositide 3-kinases","volume":"37","author":"Williams","year":"2009","journal-title":"Biochem. Soc. Trans."},{"issue":"9","key":"10.1016\/j.prp.2026.156506_bib103","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cells8091075","article-title":"Roles of mTOR signaling in tissue regeneration","volume":"8","author":"Wei","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.prp.2026.156506_bib104","first-page":"92","article-title":"mTOR: Role in cancer, metastasis and drug resistance","volume":"59","author":"Murugan","year":"2019"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41556-018-0205-1","article-title":"mTOR as a central hub of nutrient signalling and cell growth","volume":"21","author":"Kim","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"12","key":"10.1016\/j.prp.2026.156506_bib106","first-page":"1149","article-title":"PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells","volume":"48","author":"Schild","year":"2009","journal-title":"Molecular Carcinogenesis Published cooperation University Texas MD Anderson Cancer Center"},{"key":"10.1016\/j.prp.2026.156506_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-8-43","article-title":"Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis","volume":"8","author":"Pham","year":"2008","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.prp.2026.156506_bib108","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAI.0b013e3181de115b","article-title":"The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis","volume":"18","author":"Bellizzi","year":"2010","journal-title":"Appl. Immunohistochem. & Mol. Morphol."},{"key":"10.1016\/j.prp.2026.156506_bib109","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2017.02.036","article-title":"Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance","volume":"395","author":"Zhou","year":"2017","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib110","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.canlet.2014.01.014","article-title":"mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma","volume":"346","author":"Utomo","year":"2014","journal-title":"Cancer Lett."},{"issue":"17","key":"10.1016\/j.prp.2026.156506_bib111","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.3390\/cancers13174434","article-title":"Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress","volume":"13","author":"Mehra","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156506_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107869","article-title":"The diverse roles of circular RNAs in pancreatic cancer","volume":"226","author":"Chen","year":"2021","journal-title":"Pharmacol. & Ther."},{"key":"10.1016\/j.prp.2026.156506_bib113","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","article-title":"Targeting PI3K\/AKT\/mTOR network for treatment of leukemia","volume":"72","author":"Bertacchini","year":"2015","journal-title":"Cell. Mol. life Sci."},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib114","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","article-title":"Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway","volume":"142","author":"Polivka Jr","year":"2014","journal-title":"Pharmacol. & Ther."},{"key":"10.1016\/j.prp.2026.156506_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109468","article-title":"The PI3K\/Akt\/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium","volume":"66","author":"Margaria","year":"2020","journal-title":"Cell. Signal."},{"issue":"36","key":"10.1016\/j.prp.2026.156506_bib116","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.2174\/092986710794182999","article-title":"PI3K\/AKT\/mTOR inhibitors in ovarian cancer","volume":"17","author":"Mazzoletti","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib117","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.path.2020.05.007","article-title":"HER2 in colorectal carcinoma: are we there yet?","volume":"13","author":"Nowak","year":"2020","journal-title":"Surg. Pathol. Clin."},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib118","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.path.2020.05.007","article-title":"HER2 in colorectal carcinoma: are we there yet?","volume":"13","author":"Nowak","year":"2020","journal-title":"Surg. Pathol. Clin."},{"issue":"5","key":"10.1016\/j.prp.2026.156506_bib119","first-page":"7163","article-title":"Everolimus inhibits breast cancer cell growth through PI3K\/AKT\/mTOR signaling pathway","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"8","key":"10.1016\/j.prp.2026.156506_bib120","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/1541-7786.MCR-20-1066","article-title":"Emerging roles for AKT isoform preference in cancer progression pathways","volume":"19","author":"Degan","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.prp.2026.156506_bib121","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jbior.2015.05.001","article-title":"Implication of PI3K\/Akt pathway in pancreatic cancer: When PI3K isoforms matter?","volume":"59","author":"Baer","year":"2015","journal-title":"Adv. Biol. Regul."},{"issue":"6","key":"10.1016\/j.prp.2026.156506_bib122","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/CAD.0000000000000496","article-title":"Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer","volume":"28","author":"Wadhwa","year":"2017","journal-title":"Anti-Cancer Drugs"},{"issue":"17","key":"10.1016\/j.prp.2026.156506_bib123","doi-asserted-by":"crossref","first-page":"10132","DOI":"10.3390\/ijms231710132","article-title":"Targeting PI3K\/AKT\/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects","volume":"23","author":"Stanciu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156506_bib124","first-page":"147","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019"},{"key":"10.1016\/j.prp.2026.156506_bib125","first-page":"125","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside","volume":"59","author":"Alzahrani","year":"2019"},{"key":"10.1016\/j.prp.2026.156506_bib126","doi-asserted-by":"crossref","DOI":"10.1002\/inmd.70087","article-title":"Chinese pan-cancer patient genomic characteristics: A comprehensive analysis based on the National Cancer Center\u2013Clinical Diagnostics Knowledgebase real-world clinical sequencing cohort","author":"Li","year":"2026","journal-title":"Interdiscip. Med."},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib127","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/diagnostics16040523","article-title":"The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology","volume":"16","author":"Rouvinov","year":"2026","journal-title":"Diagnostics"},{"issue":"26","key":"10.1016\/j.prp.2026.156506_bib128","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1038\/s41388-019-0791-9","article-title":"FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases\/AKT axis","volume":"38","author":"Seshacharyulu","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib129","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/ijms25010391","article-title":"Copy number variations in pancreatic cancer: from biological significance to clinical utility","volume":"25","author":"Oketch","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156506_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.663787","article-title":"Integrated analysis of microarray and RNA-Seq data for the identification of hub genes and networks involved in the pancreatic cancer","volume":"12","author":"Nisar","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.prp.2026.156506_bib131","article-title":"The role and therapeutic potential of glucose metabolism in multidrug resistance of cancer","volume":"13","author":"Wang","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.prp.2026.156506_bib132","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2174\/1874467215666220128161647","article-title":"Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma","volume":"15","author":"Rajpurohit","year":"2022","journal-title":"Curr. Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib133","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/ijms25031631","article-title":"Inhibition of the RAF\/MEK\/ERK signaling cascade in pancreatic cancer: recent advances and future perspectives","volume":"25","author":"Adamopoulos","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43042-025-00809-1","article-title":"Budding Uninhibited by Benzimidazole 1 in pancreatic cancer: theoretical, mechanistic and bioinformatic insights","volume":"26","author":"Chandrasekaran","year":"2025","journal-title":"Egypt. J. Med. Hum. Genet."},{"issue":"7","key":"10.1016\/j.prp.2026.156506_bib135","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/1535-7163.MCT-19-1131","article-title":"A genome-scale CRISPR screen identifies the ERBB and mTOR signaling networks as key determinants of response to PI3K inhibition in pancreatic cancer","volume":"19","author":"Milton","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"17","key":"10.1016\/j.prp.2026.156506_bib136","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.3390\/cancers13174434","article-title":"Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress","volume":"13","author":"Mehra","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.prp.2026.156506_bib137","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.prp.2026.156506_bib138","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.3390\/cells11192952","article-title":"Role of the tumor microenvironment in regulating pancreatic cancer therapy resistance","volume":"11","author":"Deng","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib139","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1053\/j.gastro.2020.03.018","article-title":"Combination of PD-1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer","volume":"159","author":"Ma","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib140","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/cancers13040799","article-title":"Targeted therapies for pancreatic cancer: overview of current treatments and new opportunities for personalized oncology","volume":"13","author":"Leroux","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib141","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10238-022-00886-1","article-title":"Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies","volume":"23","author":"Kuznetsova","year":"2023","journal-title":"Clin. Exp. Med."},{"issue":"15","key":"10.1016\/j.prp.2026.156506_bib142","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.3390\/cancers13153920","article-title":"Therapeutic strategies targeting tumor suppressor genes in pancreatic cancer","volume":"13","author":"Kuo","year":"2021","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.prp.2026.156506_bib143","doi-asserted-by":"crossref","first-page":"10132","DOI":"10.3390\/ijms231710132","article-title":"Targeting PI3K\/AKT\/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects","volume":"23","author":"Stanciu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.prp.2026.156506_bib144","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.3390\/cancers14184351","article-title":"Targeting the metabolic rewiring in pancreatic cancer and its tumor microenvironment","volume":"14","author":"Yamamoto","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.prp.2026.156506_bib145","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","article-title":"Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer","volume":"13","author":"Falcomata","year":"2023","journal-title":"Cancer Discov."},{"issue":"22","key":"10.1016\/j.prp.2026.156506_bib146","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1158\/1078-0432.CCR-25-0758","article-title":"The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST","volume":"31","author":"Steiniche","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib147","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/1471-2407-10-368","article-title":"Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies","volume":"10","author":"Javle","year":"2010","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.prp.2026.156506_bib148","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s11523-018-0605-y","article-title":"Gemcitabine combined with the mTOR inhibitor temsirolimus in patients with locally advanced or metastatic pancreatic cancer. A hellenic cooperative oncology group phase i\/II study","volume":"13","author":"Karavasilis","year":"2018","journal-title":"Target. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156506_bib149","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.clon.2013.02.005","article-title":"A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers","volume":"25","author":"Nemunaitis","year":"2013","journal-title":"Clin. Oncol."},{"issue":"15","key":"10.1016\/j.prp.2026.156506_bib150","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1158\/1078-0432.CCR-14-2422","article-title":"First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1\/2 inhibitor AZD2014","volume":"21","author":"Basu","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.prp.2026.156506_bib151","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cancers17050785","article-title":"KRAS mutations in cancer: understanding signaling pathways to immune regulation and the potential of immunotherapy","volume":"17","author":"Uniyal","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156506_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1369136","article-title":"Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies","volume":"11","author":"Linehan","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.prp.2026.156506_bib153","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002299","article-title":"Pancreatic cancer: failures and hopes\u2014a review of new promising treatment approaches","volume":"6","author":"Cereda","year":"2025","journal-title":"Explor. Target. Anti-Tumor Ther."},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib154","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/vaccines13030292","article-title":"Targeting PI3K Signaling to Overcome Tumor Immunosuppression: Synergistic Strategies to Enhance Cancer Vaccine Efficacy","volume":"13","author":"Cui","year":"2025","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.9734\/jcti\/2025\/v15i3305","article-title":"Decoding Tumor Heterogeneity through Multi Omics: Insights into Cancer Evolution, Microenvironment and Therapy Resistance","volume":"15","author":"Ibekwe","year":"2025","journal-title":"J. Cancer Tumor Int."},{"key":"10.1016\/j.prp.2026.156506_bib156","doi-asserted-by":"crossref","unstructured":"Co, I.L.Y. (2023). An Engineered 3D Co-Culture Model of Macrophages and Pancreatic Cancer Organoids to Explore Cellular Interactions in the Tumour Microenvironment (Doctoral dissertation).","DOI":"10.1101\/2023.07.13.548899"},{"issue":"12","key":"10.1016\/j.prp.2026.156506_bib157","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3390\/cancers16122240","article-title":"Pancreatic ductal adenocarcinoma (PDAC): a review of recent advancements enabled by artificial intelligence","volume":"16","author":"Mukund","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156506_bib158","first-page":"E01","article-title":"Mevalonate pathway in pancreatic ductal adenocarcinoma: mechanisms driving metabolic and cellular plasticity","volume":"3","author":"Duttenhefner","year":"2025","journal-title":"Cancer Pathog. Ther."},{"issue":"3","key":"10.1016\/j.prp.2026.156506_bib159","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10353-023-00814-x","article-title":"Personalized treatment in localized pancreatic cancer","volume":"56","author":"Neoptolemos","year":"2024","journal-title":"Eur. Surg."},{"issue":"7","key":"10.1016\/j.prp.2026.156506_bib160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/nu8070433","article-title":"Curcumin anticancer studies in pancreatic cancer","volume":"8","author":"Bimonte","year":"2016","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.prp.2026.156506_bib161","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2174\/1381612828666220302153201","article-title":"Phyto-targeting the CEMIP expression as a strategy to prevent pancreatic cancer metastasis","volume":"28","author":"Periyasamy","year":"2022","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.prp.2026.156506_bib162","first-page":"1593","article-title":"Curcumin inhibits superoxide dismutase-induced epithelial-to-mesenchymal transition via the PI3K\/Akt\/NF-\u03baB pathway in pancreatic cancer cells","volume":"52","author":"Li","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2026.156506_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110116","article-title":"Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NF\u03baB activation","volume":"127","author":"Qian","year":"2020","journal-title":"Biomed. & Pharmacother."},{"issue":"9","key":"10.1016\/j.prp.2026.156506_bib164","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.32604\/or.2025.065222","article-title":"Polyphenols in Pancreatic Cancer Management: Exploring the Roles and Mechanisms of Resveratrol and Epigallocatechin","volume":"33","author":"de la Garza-Kalife","year":"2025","journal-title":"Oncol. Res."},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib165","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jfda.2019.07.001","article-title":"Quercetin facilitates cell death and chemosensitivity through RAGE\/PI3K\/AKT\/mTOR axis in human pancreatic cancer cells","volume":"27","author":"Lan","year":"2019","journal-title":"J. Food Drug Anal."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib166","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/4393266","article-title":"Quercetin impact in pancreatic cancer: an overview on its therapeutic effects","volume":"2021","author":"Asgharian","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib167","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12935-022-02677-w","article-title":"Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets","volume":"22","author":"Asgharian","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"12","key":"10.1016\/j.prp.2026.156506_bib168","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114573","article-title":"Dose-dependent AMPK-dependent and independent mechanisms of berberine and metformin inhibition of mTORC1, ERK, DNA synthesis and proliferation in pancreatic cancer cells","volume":"9","author":"Ming","year":"2014","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib169","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/1381612826666200928155728","article-title":"Berberine exerts anti-cancer activity by modulating adenosine monophosphate-activated protein kinase (AMPK) and the phosphatidylinositol 3-kinase\/protein kinase B (PI3K\/AKT) signaling pathways","volume":"27","author":"Huang","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.prp.2026.156506_bib170","doi-asserted-by":"crossref","DOI":"10.2174\/0113892002393013250812093213","article-title":"Natural Compounds as Potential Therapeutics for Pancreatic Cancer: A Narrative Review","author":"Lin","year":"2025","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.prp.2026.156506_bib171","first-page":"45","article-title":"Nutraceuticals for Prevention and Treatment of Cancer","volume":"2","author":"Das","year":"2022","journal-title":"Handb. Nutraceuticals Nat. Prod. Biol. Med. Nutr. Prop. Appl."},{"issue":"1","key":"10.1016\/j.prp.2026.156506_bib172","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/cancers11010028","article-title":"Flavonoids in cancer and apoptosis","volume":"11","author":"Abotaleb","year":"2018","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.prp.2026.156506_bib173","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.4071","article-title":"Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK\/mTOR signaling pathways","volume":"42","author":"Zamanian","year":"2024","journal-title":"Cell Biochem. Funct."},{"issue":"10","key":"10.1016\/j.prp.2026.156506_bib174","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00432-016-2178-4","article-title":"Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification","volume":"142","author":"Bhaw-Luximon","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156506_bib175","doi-asserted-by":"crossref","DOI":"10.12775\/QS.2024.36.56451","article-title":"Repurposing Metformin: Potential as a Prevention, Treatment and Adjunct Therapy in Pancreatic Cancer","volume":"36","author":"Kamizela","year":"2024","journal-title":"Qual. Sport"},{"issue":"16","key":"10.1016\/j.prp.2026.156506_bib176","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.3390\/cancers13163946","article-title":"Drug repurposing, an attractive strategy in pancreatic cancer treatment: preclinical and clinical updates","volume":"13","author":"De Lellis","year":"2021","journal-title":"Cancers"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:27:10Z","timestamp":1778747230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826001597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":176,"alternative-id":["S0344033826001597"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156506","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2\u2013TP53, EGFR, and PI3K\/AKT\/mTOR","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156506"}}